IFNG and hemophagocytic syndrome: Emapalumab, a recombinant human monoclonal antibody directed against IFNγ, has been recently approved for use in patients with primary HLH that is refractory, recurrent, progressive or intolerant to conventional HLH therapy (19, 20).